First Quadrant L P CA grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6,526.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 129,815 shares of the pharmaceutical company’s stock after acquiring an additional 127,856 shares during the quarter. First Quadrant L P CA owned about 0.05% of Vertex Pharmaceuticals worth $19,737,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of VRTX. Northwestern Mutual Wealth Management Co. boosted its position in shares of Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after acquiring an additional 132 shares during the last quarter. FNY Partners Fund LP boosted its position in shares of Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after acquiring an additional 900 shares during the last quarter. Dupont Capital Management Corp bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $186,000. State of Alaska Department of Revenue bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $197,000. Finally, Tocqueville Asset Management L.P. bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $203,000. Hedge funds and other institutional investors own 93.36% of the company’s stock.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 150.11 on Monday. The stock’s 50 day moving average price is $152.78 and its 200 day moving average price is $138.86. The stock has a market cap of $37.85 billion, a price-to-earnings ratio of 144.20 and a beta of 1.73. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. During the same quarter in the prior year, the company earned $0.16 EPS. Vertex Pharmaceuticals’s revenue was up 39.7% on a year-over-year basis. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.73 earnings per share for the current year.
In related news, SVP Paul M. Silva sold 1,289 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $151.80, for a total transaction of $195,670.20. Following the transaction, the senior vice president now owns 17,923 shares of the company’s stock, valued at approximately $2,720,711.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP David Altshuler sold 1,796 shares of the stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $160.00, for a total value of $287,360.00. Following the transaction, the executive vice president now directly owns 107,807 shares in the company, valued at approximately $17,249,120. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,700 shares of company stock worth $4,586,808. 1.80% of the stock is owned by corporate insiders.
A number of research analysts have recently commented on the company. Raymond James Financial, Inc. upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $181.00 target price for the company in a research report on Wednesday, July 19th. J P Morgan Chase & Co set a $175.00 price target on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Oppenheimer Holdings, Inc. raised their price target on Vertex Pharmaceuticals from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Finally, Robert W. Baird restated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have assigned a buy rating to the stock. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $169.74.
TRADEMARK VIOLATION WARNING: “First Quadrant L P CA Boosts Stake in Vertex Pharmaceuticals Incorporated (VRTX)” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/30/first-quadrant-l-p-ca-boosts-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
What are top analysts saying about Vertex Pharmaceuticals Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vertex Pharmaceuticals Incorporated and related companies.